NKGN 8-K 2026-01-16

NKGen Biotech, Inc. (NKGN) 8-K dated 2026-01-16 — accession 0001213900-26-005260.

NKGen Biotech, Inc. (NKGN) is a biotechnology company listed on US.

NKGen Biotech, Inc. filed a 8-K on 2026-01-16. Accession 0001213900-26-005260.

This 8-K covers: Material agreement (Item 1.01), New debt obligation (Item 2.03), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported NKGN revenue for 2023-12-31 was $0. Net income was -$83.0M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. NKGN currently screens at market cap $22.4M.

Not investment advice. The NKGN SEC hub lists recent forms. The stock page is the research view.